港股详情

本页面由TTMF Limited提供服务

翰思艾泰-B待上市

成交量：- -

成交额：- -

市值：- -

市盈率：- -

高：- -

开：- -

低：- -

收：- -

52周最高：- -

52周最低：- -

股本：27.26亿

香港流通股本：9.87亿

量比：- -

换手率：- -

股息：- -

股息率：- -

净资产收益率：--

总资产收益率：--

市净率：--

市盈率(LYR):- -

市销率: 0.00

1

开始申购

12/15

2

申购截止

12/18 09:30

3

公布中签

12/19

4

暗盘

12/22 16:15 - 18:30

5

挂牌上市

12/23

总览公司新闻资讯公告

新股招股｜翰思艾泰-B今日起招股，一手入场费3232.27港元

老虎资讯综合

翰思艾泰-B于12月15日至12月18日招股预计12月23日上市

《新股》翰思艾泰(03378.HK)招股入场费3,232.27元引7名基石投资者

阿斯达克财经

创新药企扎堆港股IPO

21世纪经济报道

翰思艾泰通过港交所聆讯，即将上市

新股消息 | 翰思艾泰递表港交所

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/hans/stock/03378/news"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"03378","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"03378\",,,,,undefined,":{"symbol":"03378","market":"HK","secType":"STK","nameCN":"翰思艾泰-B","latestPrice":0,"timestamp":1765785600000,"preClose":0,"halted":7,"volume":0,"delay":0,"floatShares":986700000,"shares":2726200000,"eps":0,"marketStatus":"待上市","change":0,"latestTime":"12-15 16:00:00","open":0,"high":0,"low":0,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1766453400000},"marketStatusCode":8,"adr":0,"listingDate":1766419200000,"exchange":"SEHK","adjPreClose":0,"openAndCloseTimeList":[[1765762200000,1765771200000],[1765774800000,1765785600000]],"volumeRatio":0,"ipoDetail":{"name":"翰思艾泰－Ｂ","exchange":"SEHK","listingDate":"2025-12-23","sharesOutstanding":136218830,"sharesFloat":136218830,"offerAmount":18321000,"priceRange":"28.000 - 32.000","market":"HK","openProspectusDate":"2025-12-15","openProspectusUrl":"https://www1.hkexnews.hk/listedco/listconews/sehk/2025/1215/2025121500028_c.pdf","purchaseBeginDate":"2025-12-15","purchaseEndDate":"2025-12-18","winningDate":"2025-12-22","currency":"HKD","minPurchaseQuantity":100,"peRate":-33.08,"use":"1、约35%或173.7百万港元将用于公司的核心产品（即HX009）的研发；\n2、约33%或163.8百万港元将用于公司的主要产品（即HX301及HX044）的研发；\n3、约17%或84.4百万港元将用于公司其他重要产品的研发；\n4、约5%或25.0百万港元将用于为商业化及╱或业务发展活动提供资金；\n5、约10%或49.4百万港元将用于营运资金及其他一般企业用途。","industryId":"204005","industryName":"医疗保健","business":"公司是一家拥有结构生物学、转化医学及临床开发方面自主专业技术及经验的创新生物科技公司，旨在开发新一代免疫疗法。","subscribed":10.65,"marketCap":3814000000,"minimumCapital":3232.27,"overAllotment":true,"lotSize":100,"issueOpenRate":0.1,"subscribeGear":"100,200,300,400,500,600,700,800,900,1000,1500,2000,2500,3000,3500,4000,4500,5000,6000,7000,8000,9000,10000,20000,30000,40000,50000,60000,70000,80000,90000,100000,200000,300000,400000,500000,600000,700000,800000,916000"},"greyMarketDetail":{"greyDate":"2025-12-22","greyDateTimestamp":1766332800000,"greyOpeningTime":1766391300000,"greyClosingTime":1766399400000,"showGreyQuote":false,"openProspectusDate":"2025-12-15","listingDate":"2025-12-23"},"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"000905","market":"SZ","secType":"STK","nameCN":"厦门港务","latestPrice":14.15,"timestamp":1765782000000,"preClose":13.88,"halted":0,"volume":147436700,"delay":0,"premium":"-100.00"}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"03378\",,,,,undefined,":{"symbol":"03378","floatShares":986700000,"roa":"--","roe":"--","lyrEps":0,"shares":2726200000,"dividePrice":0,"high":0,"amplitude":0,"preClose":0,"low":0,"week52Low":0,"pbRate":"--","psRate":"0.00","week52High":0,"institutionHeld":0,"latestPrice":0,"eps":0,"divideRate":0,"volume":0,"delay":0,"ttmEps":0,"open":0},"@#url:\"https://hktrade.skytigris.com/ipos/general/03378\",,undefined,":{"id":9294,"type":"COMMON","ipoName":"03378-IPO","symbol":"03378","companyName":"翰思艾泰-B","market":"HK","currency":"HKD","status":"OPEN","underwriter":"工银国际融资有限公司","lotSize":100,"minQty":100,"expectedOfferingSize":18321000,"openingDate":1765762200000,"closingDate":1766021400000,"commonClosingDate":1766021400000,"allotmentDate":1766073600000,"listDate":1766419200000,"marginable":true,"marginRate":10,"latestPrice":32,"minPrice":28,"maxPrice":32,"prospectusUrl":"https://www1.hkexnews.hk/listedco/listconews/sehk/2025/1215/2025121500028_c.pdf","allowedQuantities":[100,200,300,400,500,600,700,800,900,1000,1500,2000,2500,3000,3500,4000,4500,5000,6000,7000,8000,9000,10000,20000,30000,40000,50000,60000,70000,80000,90000,100000,200000,300000,400000,500000,600000,700000,800000,916000],"interestRate":0,"recommend":false,"isHint":false,"interestStartDate":1765987200000,"interestEndDate":1765987200000,"delayAllocate":false,"isSupportGreyMarket":true,"greyMarketTradeDate":1766391300000,"transactionRate":0.010085,"gstFeeRate":0,"rank":0,"subscribed":false,"signed":false,"financingInfos":[{"ipoName":"03378-IPO","financingId":55991,"type":1,"availableFundLimit":3232.27,"piAvailableAmountLimit":0,"piMaxAvailableAmountLimit":-1,"piMinSubscribeAmount":0,"piMaxSubscribeAmount":-1,"minSubscribeLimit":32322.7,"maxSubscribeLimit":-1,"marginRate":10,"interestRate":0,"openTime":1765762200000,"closeTime":1766021400000,"isAtValidTime":true,"subscriptionMethod":"FINANCING","processFee":0,"supportPI":false,"applyFundLimit":3232.27,"threshold":8000000000,"isAvailable":false},{"ipoName":"03378-IPO","financingId":55984,"type":4,"availableFundLimit":3232.27,"piAvailableAmountLimit":0,"piMaxAvailableAmountLimit":-1,"piMinSubscribeAmount":0,"piMaxSubscribeAmount":-1,"minSubscribeLimit":0,"maxSubscribeLimit":-1,"marginRate":100,"interestRate":0,"openTime":1765762200000,"closeTime":1766021400000,"isAtValidTime":true,"subscriptionMethod":"CASH","processFee":0,"supportPI":false,"applyFundLimit":3232.27,"threshold":10000000000,"isAvailable":false}],"financingNotifyEnabled":false,"financingNotifySubscribed":false,"subscriptionMethods":[{"method":"CASH","closeTime":1766021400000,"available":false,"messageCode":"AVAILABLE_FUND_LIMIT","minAvailableFundLimit":3232.27},{"method":"FINANCING","closeTime":1766021400000,"available":false,"messageCode":"AVAILABLE_FUND_LIMIT","minAvailableFundLimit":3232.27}],"latestClosingDate":1766021400000,"subscribedFinanceRatio":10.65,"subscribedRatio":10.65,"forecastRatio":12.99,"raiseMoney":58630000.00000001,"totalMargin":624470000,"quoteInfoUpdatedAt":1765787692874,"prospectusUpdatedAt":1765786652000,"forecastMarketValue":4086564900,"minForecastMarketValue":3814127240,"maxForecastMarketValue":4359002560,"sharesOutstanding":136218830,"business":"公司是一家拥有结构生物学、转化医学及临床开发方面自主专业技术及经验的创新生物科技公司，旨在开发新一代免疫疗法。","greyOpeningTime":1766391300000,"greyClosingTime":1766399400000,"tradable":true},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"03378\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1183827692","title":"新股招股｜翰思艾泰-B今日起招股，一手入场费3232.27港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1183827692","media":"老虎资讯综合","labels":[],"top":1,"itemType":null,"share":"https://ttm.financial/m/news/1183827692?lang=zh_cn&edition=fundamental","pubTime":"2025-12-15 11:08","pubTimestamp":1765768110,"startTime":"0","endTime":"0","summary":"12月15日，$翰思艾泰-B $ 发布公告，于12月15日-12月18日招股，公司拟全球发售约1832.1万股股份，预期将于12月23日上市。申购阶梯：每手100股，入场费3232.27港元。乙组门槛为30万股，申购所需资金约969.68万港元。于往绩记录期间及直至最后实际可行日期，公司已在澳大利亚及中国完成HX009的I期临床试验。","market":"hk","thumbnail":"https://static.tigerbbs.com/3153c88188d79bb8182b93c4fdd43636","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/3153c88188d79bb8182b93c4fdd43636"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":"新股招股｜翰思艾泰-B今日起招股，一手入场费3232.27港元","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03378"],"gpt_icon":1},{"id":"2591695019","title":"翰思艾泰-B于12月15日至12月18日招股 预计12月23日上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2591695019","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591695019?lang=zh_cn&edition=fundamental","pubTime":"2025-12-15 09:51","pubTimestamp":1765763462,"startTime":"0","endTime":"0","summary":"翰思艾泰-B于2025年12月15日至12月18日招股，该公司拟全球发售1832.1万股，其中香港发售占10%，国际发售占90%，每股发售价28-32港元。每手100股，预期股份将于2025年12月23日在联交所开始买卖。公司目前拟将有关全球发售所得款项净额用作以下用途：约35%将用于公司的核心产品的研发；约33%将用于公司的主要产品的研发；约17%将用于公司其他重要产品的研发；约5%将用于为商业化及╱或业务发展活动提供资金；约10%将用于营运资金及其他一般企业用途。","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2025/12/15095154693103.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1535","BK1173","03378"],"gpt_icon":0},{"id":"2591695259","title":"《新股》翰思艾泰(03378.HK)招股入场费3,232.27元  引7名基石投资者","url":"https://stock-news.laohu8.com/highlight/detail?id=2591695259","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591695259?lang=zh_cn&edition=fundamental","pubTime":"2025-12-15 09:21","pubTimestamp":1765761660,"startTime":"0","endTime":"0","summary":"拥有结构生物学、转化医学及临床开发方面自主专业技术及经验的生物科技公司翰思艾泰-B今日起招股，共发售1,832.1万股，当中香港公开发售183.21万股，每股招股价28至32元，以一手100股计，入场费3,232.27元，集资最多约5.9亿元，招股期至12月18日，预计本月23日挂牌。公司引入7名基石投资者，包括富德资源、Sage Partners Master Fund、国泰君安证券投资(香港)有限公司、TFI Investment Fund SPC、Main Source Capital Limited及YStem Capital、春雷资本，总投资额9,337万元。","market":"hk","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180815142909241_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180815142909241_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1490292/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["03378","BK1535","BK1173"],"gpt_icon":0},{"id":"2590457696","title":"创新药企扎堆港股IPO","url":"https://stock-news.laohu8.com/highlight/detail?id=2590457696","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590457696?lang=zh_cn&edition=fundamental","pubTime":"2025-12-12 15:45","pubTimestamp":1765525500,"startTime":"0","endTime":"0","summary":"炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！　　12月以来，港股生物医药板块IPO市场热度持续攀升：嘉和生物、翰思艾泰、明基医院、华生物相继通过聆讯，和美药业、高光制药、石药创新、君赛生物陆续递交上市申请，中国证监会国际合作司亦于近期披露英硅智能境外发行上市的备案通知书。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/marketresearch/2025-12-12/doc-inhaprxm5183321.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/marketresearch/2025-12-12/doc-inhaprxm5183321.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["159992","BK1161","BK1574","03378","06978"],"gpt_icon":0},{"id":"2588833998","title":"翰思艾泰通过港交所聆讯，即将上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2588833998","media":"医药笔记","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588833998?lang=zh_cn&edition=fundamental","pubTime":"2025-12-04 18:39","pubTimestamp":1764844748,"startTime":"0","endTime":"0","summary":"▎Armstrong2025年12月3日，翰思艾泰港交所IPO申请通过聆讯，即将上市。翰思艾泰成立于2014年，2016年起开始搭建研发管线，核心管线HX009为一款PD-1/SIRPα双抗，目前处于二期临床阶段。翰思艾泰成立以来经历多轮融资，2024年8月完成B+轮融资，投后估值16.15亿元。翰思艾泰最新股权结构如下，贝达药业持股5.45%，龙磐资本持股12.43%，金斯瑞持股1.53%。总结翰思艾泰还曾于2016年引进康方生物研发的PD-1抗体HX008，后于2019年转让给乐普生物，并于2022年获批上市。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251204203627a4ccaba3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251204203627a4ccaba3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0856984785.SGD","SG9999004220.SGD","HEXmain","LU0048580855.USD","LU0797268264.HKD","IE00BKZH1Z71.USD","LU0052750758.USD","LU0096374516.USD","SG9999001093.SGD","LU0630378429.USD","HKXCY","LU0211977185.USD","LU0630378692.HKD","LU0831103253.SGD","LU0359201612.USD","LU0149721374.USD","LU0488056044.USD","LU0762541174.USD","LU0067412154.USD","LU0359201885.HKD","LU0607220059.USD","LU0348816934.USD","LU0791591158.USD","LU0516422952.EUR","LU0577902298.EUR","LU0197773673.USD","LU2039709279.SGD","LU1048596156.SGD","BK1610","LU0261947096.USD","LU0605514214.HKD","LU0561508036.HKD","SG9999001846.SGD","03378","LU0577902538.SGD","LU0831093199.SGD","LU0791590937.USD","LU0197773160.USD","LU0061477393.USD","SGXZ90724238.SGD","80388","LU0516423174.USD","LU1282648689.USD","00388","BK1521","LU0873338254.USD","LU0501845795.SGD","LU1282649810.SGD","IE00BZ08YR35.GBP","LU0384037296.USD","LU0762540952.USD"],"gpt_icon":0},{"id":"2588045735","title":"新股消息 | 翰思艾泰递表港交所","url":"https://stock-news.laohu8.com/highlight/detail?id=2588045735","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588045735?lang=zh_cn&edition=fundamental","pubTime":"2025-12-03 20:20","pubTimestamp":1764764428,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，据港交所12月3日披露，翰思艾泰生物医药科技(武汉)股份有限公司(简称：翰思艾泰)递表港交所主板，工银国际为其独家保荐人。招股书披露，翰思艾泰是一家拥有结构生物学、转化医学及临床开发方面自主专业技术及经验的生物科技公司。自2016年起，公司开发了产品管线，包括一款核心产品及九款其他管线的候选产品。据悉，核心产品HX009是一种自主研发的抗PD-1(一种免疫检查点受体)/SIRPα双功能抗体融合蛋白。于往绩记录期间及直至最后实际可行日期，公司已在澳大利亚及中国完成HX009的I期临床试验。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1377348.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HEXmain","03378"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":6,"code":"91000000","status":"200"}]}}